Lisa Henderson

Employer-sponsored health plans create an increasingly cloudy path to access.

COVID pandemic brings increased attention to other infectious diseases.

While pharma has reached new heights in vaccine development, many questions remain around the lasting effects of COVID and how future therapies can curb them.

Examining the incumbent and imminent workforce.

Latest disease-modifying market entrant for SMA addresses administration, access gaps.

Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.

Looking Back at 2003–2006.

Still plenty to learn about the virus even after year-plus long pandemic

Recent roundtable highlights need for biopharma to enter ESG conversation.

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.

Combined powers of synbio and biopharma point to bright future for industry.

Bridging science and business with the end user in mind.

Throwback scientist and entrepreneur leads quest to maximize gains in population health.

Pharm Exec's 2021 class of EPL winners showcase the many career trajectories through biopharma.

Ethics and diversity on full display across pharma industry.

Building on early achievements as a research scientist and drug inventor, Rod MacKenzie, today the leader of global product development at Pfizer—and latest HBA Honorable Mentor—has devoted much of his career to helping others succeed, including advancing efforts to break down gender barriers in pharma.

Industry makes large investments toward public health issues exposed by pandemic.

Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching.

Embracing the new, holistic views of pharma in 2021.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.

A brief look into how the Gene Editing Institute researching the diversity of responses in African-American regenerative cells to various forms of CRISPR.

Previewing executive trends thought of by leaders in the pharma industry.

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Uncovering fish oil derivative’s benefit for heart health.

A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

Former physician and clinical researcher Antony Loebel, now president and CEO of Sunovion Pharmaceuticals, discusses his career-long mission to advance novel treatments for patients suffering from serious and underserved CNS disorders.